← Eichor
Condition: Recurrent Childhood Acute Lymphoblastic Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Recurrent Childhood Acute Lymphoblastic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS
Phase 1 · 19 location(s) · Children's Oncology Group · NCT06247787CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
Phase 1/Phase 2 · 11 location(s) · University Hospital Tuebingen · NCT05366218CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transp
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT07257419Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Soli
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT06620302FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myel
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06609928Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 · 1 location(s) · Florida International University · NCT05857969Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggr
Phase 1/Phase 2 · 6 location(s) · University of Alberta · NCT03938987HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cel
NA · 1 location(s) · Peking University People's Hospital · NCT06581081Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Ly
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03136146Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
Phase 2 · 7 location(s) · Ho Joon Im · NCT05827549A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Phase 2 · 10 location(s) · Chongqing Precision Biotech Co., Ltd · NCT05334823Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Mali
Phase 1 · 2 location(s) · Sumithira Vasu · NCT05418088
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.